ONCOLOGY MARKET ANALYSIS

Mohameed Ahsraf

Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted   erapy, Immunotherapy, and Hormonal   erapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 – 2025.   e global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.Cancer is a disease, which involves the abnormal growth of cells that results in the formation of a tumor. However benign tumors are not cancers.

   e abnormal tumor cells have the tendency to spread to other local tissues and may also spread to di erent parts of body through blood and lymphatic system. Di erent types of cancers such as lung cancer, colorectal, breast cancer, and others are predominant among the populace. Treatment of cancer depends upon the stages of the disease progression. Chemotherapy is majorly used in the earlier stages whereas other therapy options such as targeted therapy drugs, immunological therapy drugs are used in late stage. Cancer has a widespread prevalence worldwide, which has led to rise in demand for cancer drugs.

   e key factors that are responsible for the growth of the onmarket.   e global oncology/cancer drugs market is segmented based on drug class type, indication, and region. On the basis of drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy, and others. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Paci c (China, Japan, Australia, India, South Korea, and rest of Asia-Paci c), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

According to drug class type, the targeted therapy segment occupied the largest oncology/cancer drugs market share in 2017.   is is due to the ability of targeted therapies to kill only malignant cells, higher e cacy and higher survival rates associated with their use.   e immunotherapy segment is expected to show fastest growth during the forecast period, registering a CAGR of 10.4%.   is is attributed to surge in incidence of cancer worldwide and high unmet medical needs